Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Developing a cell line standard for HER2/neu.

Anthony Rhodes1

  • 1Faculty of Applied Sciences, University of the West of England, Bristol, Frenchay Campus, Coldharbour Lane, Bristol BS16 1QY, UK. Anthony.Rhodes@uwe.ac.uk

Cancer Biomarkers : Section a of Disease Markers
|December 29, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gut Microbiota of Sarawak's "Orang Ulu" Indigenous Community in East Malaysia Reveals Vanish Microbes: A Comparison With Urban Communities.

British journal of biomedical science·2026
Same author

Corrigendum: Reproducibility of Immunohistochemical Testing of Estrogen Receptors, Progesterone Receptors, Human Epidermal Growth Factor Receptor-2 (HER2) and Ki-67 in Vietnam.

British journal of biomedical science·2025
Same author

Reproducibility of Immunohistochemical Testing of Estrogen Receptors, Progesterone Receptors, Human Epidermal Growth Factor Receptor-2 (HER2) and Ki-67 in Vietnam.

British journal of biomedical science·2025
Same author

CCAT 1- A Pivotal Oncogenic Long Non-Coding RNA in Colorectal Cancer.

British journal of biomedical science·2023
Same author

Biomedical Science and New Frontiers.

British journal of biomedical science·2022
Same author

AAC and Artificial Intelligence (AI).

Topics in language disorders·2021
Same journal

A causal association between Epstein-Barr virus infection and lung cancer: A two-sample Mendelian Randomization study.

Cancer biomarkers : section A of Disease markers·2026
Same journal

In silico analysis suggests ELL2 as a survival-associated cross-tissue biomarker in gastric cancer.

Cancer biomarkers : section A of Disease markers·2026
Same journal

The clinical assessment of miR-34a and miR-135b panel as promising diagnostic biomarkers predict the risk of colorectal cancer: A case-control study.

Cancer biomarkers : section A of Disease markers·2026
Same journal

Integrative multi-omics analysis-based Mendelian randomization identifies association of DNA repair-related genes with oral cancer.

Cancer biomarkers : section A of Disease markers·2026
Same journal

Stage-specific biomarkers in triple-negative breast cancer: Preliminary findings from bioinformatics approaches.

Cancer biomarkers : section A of Disease markers·2026
Same journal

Development and verification of cell cycle-related gene markers for prognosis in bladder cancer.

Cancer biomarkers : section A of Disease markers·2026
See all related articles

Developing standardized reference materials for HER2/neu testing is crucial for improving the accuracy and reproducibility of immunohistochemical assays in breast cancer diagnostics. This standardization aims to enhance clinical laboratory performance and serves as a model for future predictive marker assays.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biotechnology

Background:

  • Medical genetics advances identify key molecules in carcinogenesis, leading to targeted therapies like trastuzumab for HER2/neu-overexpressing breast cancer.
  • HER2/neu assays are critical predictive tools, but immunohistochemical analysis faces reproducibility challenges due to difficulties in standardizing sensitivity.
  • Lack of reliable standardization in HER2/neu assays hinders accurate clinical assessment and treatment selection.

Purpose of the Study:

  • To address the lack of reproducibility in HER2/neu immunohistochemical assays by developing standardized reference materials.
  • To improve the accuracy and reliability of HER2/neu testing in clinical laboratories.
  • To establish a template for standardizing other predictive molecular markers in cancer diagnostics.

Related Experiment Videos

Main Methods:

  • Development of standardized reference materials using well-characterized cell lines.
  • Implementation of external quality assurance programs utilizing these reference materials.
  • Collaboration between European and United States research groups to establish standards.

Main Results:

  • Preliminary European work demonstrated the feasibility of using cell line-based standards.
  • External quality assurance programs using cell line standards significantly improved clinical laboratory results.
  • Proposed US approach includes NIST-certifiable and commercially developed HER2/neu standards.

Conclusions:

  • Standardized reference materials are essential for reliable HER2/neu testing and improving breast cancer diagnostics.
  • Cell line-based standards and quality assurance programs can enhance the performance of clinical laboratories.
  • The developed approach for HER2/neu standardization can serve as a model for future predictive marker assays.